InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,288.61
(
0.07%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: Maciste post# 23639

Thursday, 11/08/2012 7:19:22 PM

Thursday, November 08, 2012 7:19:22 PM

Post# of 80490
ARIA is at an inflection point. It's no longer a small bio being driven primarily by clinical trial results. The company now sports a healthy $3.5 billion market cap. The only catalyst the market is focused on now is ponatinib's launch. Earlier approval = sooner sales. Broader label = greater sales. Once the company demonstrates ponatinibs ability to take market share from gleevec/tasigna/sprycel, it'll be reflected in the share price. Until then, we'll trade with the general market.
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up